Business Model & Revenue
Cardio Diagnostics operates as a molecular diagnostics company leveraging AI-enhanced epigenetic and genetic testing for cardiovascular disease detection. The company has developed two commercially available tests: Epi+Gen CHD, which combines epigenetic methylation patterns with genetic variants to assess heart disease risk, and PrecisionCHD, which detects INOCA (Ischemia with Non-Obstructive Coronary Arteries) and MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) — conditions representing a significant unmet clinical need. Revenue is generated through test pricing to healthcare providers, health systems, and eventually through Medicare reimbursement once the national coverage determination is finalized. The company also generates revenue through its growing provider network, which pays for test processing and interpretation services.
Financial Highlights
Quarterly Revenue and Profitability (Last 4 Quarters)
| Quarter | Revenue | Net Loss | EPS | Operating Expenses |
|---|---|---|---|---|
| Q3 2025 | $2,855 | ($1,714,536) | ($0.98) | $1,714,452 |
| Q2 2025 | $7,475 | ($1,683,199) | ($0.97) | $1,686,174 |
| Q1 2025 | $940 | ($1,635,064) | ($0.97) | $1,631,500 |
| Q4 2024 | $4,512 | ($1,519,308) | ($0.01)* | $1,520,914 |
*Q4 2024 EPS reflects pre-reverse-split share count of ≈4.18M. Post-split equivalent ~($0.97).
Trailing 12-Month Income Summary
| Metric | TTM Value | Notes |
|---|---|---|
| Total Revenue | $15,782 | Pre-commercial; test volume ramping |
| Total Net Loss | ($6,552,107) | ≈$1.64M avg burn/quarter |
| R&D Expense | ≈$360K | Included in operating expenses |
| Operating Cash Burn | ~($5.77M) | Sum of 4 quarters operating CF |
| Gross Margin | ≈100% | Minimal COGS; opex-heavy structure |
Balance Sheet Snapshot (as of September 30, 2025)
| Item | Amount |
|---|---|
| Total Assets | $8,788,902 |
| Current Assets (incl. cash) | $6,927,472 |
| Non-Current Assets | $1,861,430 |
| Total Liabilities | $637,331 |
| Current Liabilities | $398,448 |
| Stockholders' Equity | $8,151,571 |
| Shares Outstanding (approx.) | ≈1.46M (post reverse split) |
Cash Runway Estimate
| Metric | Figure |
|---|---|
| Cash & Current Assets (Q3 2025) | ≈$6.93M |
| Quarterly Burn Rate | ≈$1.7M |
| Estimated Runway | ≈4 quarters (to mid-2026) |
Competitive Landscape
Cardio Diagnostics operates at the convergence of molecular diagnostics, AI, and preventive cardiology — a space with few direct competitors offering epigenetic cardiovascular testing at this level of specificity. The broader cardiovascular diagnostics market is dominated by imaging-based and biomarker-based tools, none of which target the genetic-epigenetic methylation patterns that CDIO's platform interrogates.
- Guardant Health (GH): Liquid biopsy pioneer focused on oncology; no cardiovascular epigenetic offering. Demonstrates that AI-enhanced blood-based diagnostics can command premium reimbursement once validated.
- Exact Sciences (EXAS): Multi-cancer early detection and Cologuard; shows the model of blood/stool-based diagnostics growing from zero revenue to billions via CMS coverage.
- Bio-Techne (TECH): Proteomics and genomics tools company; touches cardiovascular biomarkers but not a direct competitor.
- BioAffinity Technologies (BIAF): Early-stage diagnostics for lung cancer; comparable market cap range.
- Quest Diagnostics (DGX) / LabCorp (LH): Major reference labs that could become distribution partners or acquirers once CDIO achieves reimbursement.
CDIO's durable moats:
- Published peer-reviewed clinical validation in JAHA — not easily replicated
- CPT Proprietary Laboratory Analysis codes assigned — structural advantage in billing infrastructure
- Preliminary CMS gapfill pricing received — most early-stage diagnostics never reach this stage
- Patent portfolio spanning U.S. and Japan — IP protection on the core algorithm
- First-mover in INOCA/MINOCA detection via blood test — a clinically recognized unmet need
Catalysts
- CMS Final Reimbursement Decision (2026): The single most important catalyst. Preliminary gapfill pricing was received October 2024. A final positive determination would trigger commercial adoption.
- Q4 2025 Earnings Report (est. March-April 2026): First look at revenue data post-investor call campaign. Any material uptick in test volumes would be highly significant.
- Reimbursement Expansion Beyond Medicare: Private payer coverage typically follows CMS lead. A single major commercial payer decision could 10x addressable revenue.
- India Market Launch Execution: Partnership with Aimil Ltd. and Dr. Lal PathLabs for PrecisionCHD in India represents a large addressable market.
- Additional Provider Network Expansion: Company added 22+ provider organizations in 2025. A major health system partnership would signal commercial validation.
Key Risks
- Cash runway of ≈4 quarters (Q3 2025 baseline); a failed capital raise or delayed reimbursement could force severe dilution or operational shutdown
- CMS reimbursement is not guaranteed — final Medicare gapfill pricing could be denied, delayed past 2026, or set at a level that makes the business model unviable
- Trailing 12-month revenue of $15,782 means the company is functionally pre-commercial; test adoption could stall if physicians resist adding a novel blood test to standard workflows
- Current momentum is retail-driven with no confirmed fundamental catalyst for today's +25% move — the stock has a history of 50-80% reversals following similar spikes, as seen in Nov 2023
- Nano cap with ≈1.46M shares outstanding is highly susceptible to pump-and-dump dynamics, short squeezes, and institutional avoidance; liquidity is thin and spreads are wide
Our Thesis
Cardio Diagnostics occupies a unique and defensible niche: AI-enhanced epigenetic diagnostics for the #1 killer in America. Their two commercially available tests — Epi+Gen CHD and PrecisionCHD — are backed by publications in the Journal of the American Heart Association. These are CPT-coded, clinically validated blood tests with a growing provider network that added 15 new organizations in October 2025 and 7 more in February 2025. Preliminary CMS gapfill pricing was received in October 2024. Final determination could come in 2026. That is the single most important binary event for this stock.
The valuation math is straightforward. At $6.53 pre-market, market cap is ≈$9.5M. Cash on hand as of September 30, 2025 was approximately $6.35M in current assets, with minimal liabilities of $637K and equity of $8.15M — meaning investors are paying barely a 15% premium to book value. If CMS finalizes gapfill pricing at even $300/test and CDIO processes 5,000 tests annually, that's $1.5M in revenue. At a 20x forward P/S multiple, that implies a $30M market cap, or roughly $20.60/share. Conservative scenario of 3,000 tests at $300 = $900K revenue, 15x P/S = $13.5M market cap ≈ $13.00 price target. This is a 12-month speculative target.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.